Market Closed -
Canadian Securities Exchange
10:35:35 2024-04-15 am EDT
|
5-day change
|
1st Jan Change
|
0.005
CAD
|
-66.67%
|
|
0.00%
|
-50.00%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
0.7378
|
1.143
|
3.528
|
6.223
|
9.212
|
3.433
|
Enterprise Value (EV)
2 |
0.5199
|
1.34
|
3.709
|
7.246
|
11.09
|
6.581
|
P/E ratio
|
-1.9
x
|
-1.44
x
|
-0.68
x
|
-2.7
x
|
-2.14
x
|
-1.79
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,600
x
|
2,795
x
|
-
|
59.2
x
|
20.3
x
|
-
|
EV / Revenue
|
1,128
x
|
3,276
x
|
-
|
68.9
x
|
24.5
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-3,826,236
x
|
-5,033,058
x
|
-12,810,726
x
|
EV / FCF
|
-1.92
x
|
-7.13
x
|
-3.37
x
|
-6.23
x
|
-10.1
x
|
-5.53
x
|
FCF Yield
|
-52%
|
-14%
|
-29.7%
|
-16.1%
|
-9.85%
|
-18.1%
|
Price to Book
|
0.28
x
|
0.6
x
|
-27
x
|
-6.4
x
|
-4.6
x
|
-1.48
x
|
Nbr of stocks (in thousands)
|
10,218
|
10,218
|
21,038
|
27,161
|
36,919
|
47,236
|
Reference price
3 |
0.0722
|
0.1119
|
0.1677
|
0.2291
|
0.2495
|
0.0727
|
Announcement Date
|
4/30/18
|
4/30/19
|
4/29/20
|
4/30/21
|
5/6/22
|
7/7/23
|
1EUR in Million2CAD in Million3EUR Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.000461
|
0.000409
|
-
|
0.1052
|
0.4529
|
-
|
EBITDA
|
-
|
-
|
-
|
-1.894
|
-2.203
|
-0.5137
|
EBIT
1 |
-0.3584
|
-0.4644
|
-2.915
|
-1.901
|
-2.223
|
-0.5352
|
Operating Margin
|
-77,747.72%
|
-113,543.03%
|
-
|
-1,806.95%
|
-490.9%
|
-
|
Earnings before Tax (EBT)
1 |
-0.3879
|
-0.7949
|
-3.98
|
-2.114
|
-3.64
|
-1.444
|
Net income
1 |
-0.3879
|
-0.7949
|
-3.98
|
-2.114
|
-3.64
|
-1.57
|
Net margin
|
-84,152.28%
|
-194,348.66%
|
-
|
-2,009.13%
|
-803.69%
|
-
|
EPS
2 |
-0.0380
|
-0.0778
|
-0.2471
|
-0.0849
|
-0.1167
|
-0.0407
|
Free Cash Flow
1 |
-0.2705
|
-0.1878
|
-1.101
|
-1.164
|
-1.092
|
-1.191
|
FCF margin
|
-58,667.68%
|
-45,919.8%
|
-
|
-1,106.14%
|
-241.22%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/30/18
|
4/30/19
|
4/29/20
|
4/30/21
|
5/6/22
|
7/7/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
0.2
|
0.18
|
1.02
|
1.87
|
3.15
|
Net Cash position
1 |
0.22
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.5398
x
|
-0.8508
x
|
-6.129
x
|
Free Cash Flow
1 |
-0.27
|
-0.19
|
-1.1
|
-1.16
|
-1.09
|
-1.19
|
ROE (net income / shareholders' equity)
|
-14.1%
|
-34.9%
|
-447%
|
399%
|
245%
|
66.9%
|
ROA (Net income/ Total Assets)
|
-7.91%
|
-11.5%
|
-116%
|
-258%
|
-445%
|
-44.6%
|
Assets
1 |
4.904
|
6.903
|
3.418
|
0.819
|
0.8179
|
3.517
|
Book Value Per Share
2 |
0.2600
|
0.1900
|
-0.0100
|
-0.0400
|
-0.0500
|
-0.0500
|
Cash Flow per Share
2 |
0.0200
|
0.0100
|
0.0100
|
0
|
0
|
-
|
Capex
|
-
|
-
|
0
|
0.05
|
0.06
|
-
|
Capex / Sales
|
-
|
-
|
-
|
47.47%
|
13.94%
|
-
|
Announcement Date
|
4/30/18
|
4/30/19
|
4/29/20
|
4/30/21
|
5/6/22
|
7/7/23
|
|
1st Jan change
|
Capi.
|
---|
| -50.00% | 173K | | +37.08% | 5.92B | | -17.43% | 4.51B | | -9.46% | 3.15B | | +0.51% | 3.1B | | -3.53% | 2.42B | | +41.15% | 1.97B | | -5.15% | 1.68B | | +0.09% | 1.65B | | -10.38% | 1.53B |
Alternative Medicine
|